Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1365)	8/16/2005 5:21:52 PM
From: Jibacoa	Respond to of 3722

NVD Was also among the few Biotechs that were able to hold their own against the market's downcurrents today.<g> The insiders have been doing some nibbling lately. On June 2 it announced that it had received an approvable letter from the FDA for its NitroMist lingual aerosol and will not require further clinical studies, but it still needs to complete the manufacturing validation process. It also has announced that it holds 11 patents for lingual spray delivery of several other drugs. The stock was up more than 6% today. bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1365)	3/20/2006 1:56:53 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ANX Seems to have found support at the 4.15 level and has been forming a base at 4.25 <g> It has had some good upticks lately, but was not able to trade above its Feb.28 H of 4.73 (the H yesterday was 4.72 & the H so far today 4.66 <g>) It needs to close above 4.73 in order to test its Jan.30 H at 5.20 ( when it made a 52wks. H ) bigcharts.marketwatch.com It reported its 4thQ results last week and although the loss for the Q was $3.5M, its R&D expenses were $3M compared with $691Ks in 2004. For the full Yr. its R&D expenses were $8.7M compared with $2.7M in 2004 ANX closed the Yr. with $22.6M in cash, compared with $13M in 2004 (it had a private placement in July of $20M.<g> It is planning to start a PIII of its CoFactor for patients with metastatic Colorectal Ca, but will delay the start to the 2ndQ since it has requested the FDA some revisions on the protocol including an increase in the number of patients to 1200. Will see if the stock can get to the $7 level this year.<g> bigcharts.marketwatch.com Bernard